Special AT-rich sequence-binding protein 2 (SATB2) expression in colorectal carcinoma; a possible future perspective for targeted therapy

Marwa Mosaad Shakweer,Ghada Refaat Meckawy

doi:10.15171/ipp.2019.13

Marwa Mosaad Shakweer, Ghada Refaat Meckawy

Open Access

https://doi.org/10.15171/ipp.2019.13

Copy DOI

Journal: Immunopathologia Persa	Publication Date: Aug 30, 2019
License type: cc-by

Affiliation: Ain Shams University

Abstract

Special AT-rich sequence-binding protein 2 (SATB2) expression in colorectal carcinoma; a possible future perspective for targeted therapy

Highlights

Special AT-rich sequence-binding protein 2 (SATB2) expression in colorectal carcinoma; a possible future perspective for targeted therapy
The aim of this editorial is to include our insights from the most recently published researches highlighting the role of SATB2 as a cancer stem cell marker for colorectal carcinoma which would open a new scope for trials and researches on SATB2 targeted therapy
Immunotherapy with PD-1 inhibitors are used in patients with deficient mismatch repair or microsatellite instability-high (MSI-H) (1)

Summary

Introduction

Special AT-rich sequence-binding protein 2 (SATB2) expression in colorectal carcinoma; a possible future perspective for targeted therapy. The use of SATB2 (special AT rich sequence binding protein2), immunohistochemical expression in colorectal carcinoma has a well-known value as a sensitive and specific diagnostic marker. The aim of this editorial is to include our insights from the most recently published researches highlighting the role of SATB2 as a cancer stem cell marker for colorectal carcinoma which would open a new scope for trials and researches on SATB2 targeted therapy.

Results

Conclusion